Pharmacologic management of sexual dysfunction: Benefits and limitations

CNS Spectrums

Volumn 8, Issue 3, 2003, Pages 225-229

  Segraves, Robert Taylor ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b The MetroHealth System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; ANDROGEN; ANTIDEPRESSANT AGENT; APOMORPHINE; ARGININE; CITALOPRAM; CLOMIPRAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; EPHEDRINE; FLUOXETINE; FLUVOXAMINE; NEUROLEPTIC AGENT; PAPAVERINE; PAROXETINE; PHENTOLAMINE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PRASTERONE; PROSTAGLANDIN E1; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SILDENAFIL; TESTOSTERONE; TESTOSTERONE UNDECANOATE; TRAZODONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASODILATOR AGENT; YOHIMBINE; PIPERAZINE DERIVATIVE;

ANDROGEN THERAPY; CLINICAL TRIAL; DRUG EFFICACY; EJACULATION; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FEMALE; HUMAN; LIBIDO DISORDER; MALE; NAUSEA; PRIAPISM; PRIORITY JOURNAL; PSYCHIATRY; REVIEW; SEXUAL AROUSAL; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SYNCOPE; VASODILATATION; PSYCHOSEXUAL DISORDER;

FEMALE; HUMANS; MALE; PIPERAZINES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; VASODILATOR AGENTS;

EID: 0037365483     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900024469     Document Type: Review

References (79)

1. Laumann EO, Gagnon JH, Michael RT, Michaels S, eds. The Social Organization of Sexuality: Sexual Practices in the United States. Chicago. Ill: University of Chicago Press; 1994.
2. Fugl-Meyer KS. Epidemiology of female sexual function. Paper presented at: the Female Sexual Function Forum, Boston Mass: October, 2001.
3. Dunn KM. Association of sexual problems with social, psychological, and physical problems in men and women: a cross sectional survey. J Epidemiol Community Health. 1999;53:144-148.
4. Lindal E, Stefansson JG. The lifetime prevalence of psychosocial dysfunction among 55- to 57-year olds in Iceland. Soc Psychiatry Psychiatr Epidemiol. 1993;28:91-95.
5. Kennedy SH, Dickens SE, Eisfeld BS, Bagby RM. Sexual dysfunction before antidepressant therapy in major depression. J Aff Disord. 1999;56:210-208.
6. Kockott G, Pfeiffer W. Sexual disorders in nonacute psychiatric outpatients. Comprehensive Psychiatry 1996;37:56-61.
7. Wiederman MW, Pryor T, Morgan CD. The sexual experience of women diagnosed with anorexia nervosa and bulimia nervosa. Int J Eat Disorder. 1996;19:109-118.
8. Minnen AV, Kampman M. The interaction between anxiety and sexual functioning: a controlled study of sexual functioning in women with anxiety disorders. Sexual Relationship Therapy. 2000;15:47-57.
9. Zemishlany Z. Pharmacotherapy of sexual dysfunction in special populations. European Psychiatry. 2002;7(suppl 1):15s.
10. Nkanginieme I, Segraves RT. Neuropsychiatric aspects of sexual dysfunction. In: Fogel B, Schiffer R, Rao S, eds. Neuropsychiatry. Baltimore, Md; Williams & Wilkins: In press.
11. Edwards E, Muirhead GJ. Introduction. Bri J Clin Pharmacol. 2002;53:1S-3S.
12. Levine LA. Diagnosis and treatment of erectile dysfunction. Am. J Med. 2000;109(suppl 9a):3s-12s.
13. Padma-Nathan H, McMurray JG, Pullman WE. On demand IC351 (Claims) enhances erectile function in patients with erectile dysfunction. Int J Impot Res. 2001;13:2-9.
14. Klotz T, Sachse R, Heidrich A. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a Rigiscan and pharmacodynamic study. Word J Urol. 2001;19:32-39.
15. Andersson KE, Wylie MG. Receptor pharmacology related to erectile dysfunction. In: Carson CC, Kirby RS, Goldstein I, eds. Textbook of Erectile Dysfunction. Oxford, England: Oxford University Press; 1999;123-132.
16. Virag R, Becher E, Carrier S, et al. Local pharmacological treatment modalities. In: Jardin A, Wagner G, Khoury S, eds. Erectile Dysfunction. Plymouth, United Kingdom: Health Publication Ltd.; 2000;241-304.
17. Segraves RT, Althof A. Psychotherapy and pharmacotherapy for sexual disorders. In: Nathan P, Gorman JS, eds. A Guide to Treatments That Work. 2nd ed. New York, NY: Oxford University Press; 2002:497-524.
18. Mulhall JP, Goldstein I. Oral agents in the management of erectile dysfunction. In: Carson CC, Kirby RS, Goldstein I, eds. Textbook of Erectile Dysfunction. Oxford, England: Oxford University Press; 1999:309-315.
19. Lal S, Ackman D, Thavundayil J, Kieley M, Etienne P. Effect of apomorphine, a dopamine receptor agonist on penile tumescence in normal subjects. Progress in Neuropharmacology. 1984;8:695-699.
20. Lal S, Laryea E, Thavundayil J, et al. Apomorphine-induced penile tumescence in impotent patients. Preliminary findings. Prog Neuropharmacol Biol Psychiatry. 1987;143:819-820.
21. Danjou P, Alexander L, Warat D, Combiez L, Perch A. Assessment of erectogenic properties of apomorphine and yohimbine in man. J Clin Pharmacol. 1988;26:733-739.
22. Segraves RT, Bari M, Segraves KB, Spirnak P. Effect of apomorphine on penile tumescence in men with psychogenic impotence. J Urol. 1991;145:1174-1175.
23. Morales A. Apomorphine to uprima: the development of a practical erectogenic drug: a personal perspective. Int J Impot Res. 2001;13(suppl 3):S29-S34.
24. Heaton J. Characterizing the benefit of apomorphine SL (uprima as an optimized treatment for the representative populations with erectile dysfunction. Int J Impo Res. 2001;13(suppl 3)S35-S39.
25. Von Kietz AT, Stroberg P, Bukofzer S, Mallard N, Hibberd M. A European multicenter study to evaluate the tolerability of apomorphine sublingual administered in a forced dose-escalation regimen in patients with erectile dysfunction. BJU International. 2002;89:409-415.
26. Bukofzer S, Livesay N. Safety and tolerability of apomorphine SL (Uprima). Int J Impot Res. 2001;13(suppl 3):S40-S44.
27. Giulano F, Allard J. Dopamine and sexual function. Int J Impot Res. 2001;13(suppl 3):S18-S28.
28. Andersson KE. Neurophysiology/pharmacology of erection. Int J Impot Res. 2001;13(suppl 3):S8-S17.
29. Rosen RC, Padma-Nathan H, Goldstein I. Process of care model for the management of erectile dysfunction in the primary care setting. In Carson CC, Kirby RS, Goldstein I, eds. Textbook of Erectile Dysfunction. Oxford, England: Oxford University Press; 1999;497-503.
30. Segraves RT. New treatment for erectile dysfunction. Curr Psychiatry Reports. 2002;2:206-210.
31. Olsson AM, Speakman MJ, Dinsmore WW, et al. Sildenafil citrate (Viagra) is effective and well tolerated for treating erectile dysfunction of psychogenic or mixed etiology. Int J Clin Practice. 2000;54:561-566.
32. McCarthy B. Relapse prevention strategies and techniques with erectile dysfunction. J Sex Marital Ther. 2001;27:1-8.
33. Pallas J, Levine SB, Althof SE, Risen CB. A study using Viagra in a mental health practice. J Sex Marital Ther. 2000;26:41-50.
34. Wise, TN. Psychosocial side effects of sildenafil therapy for erectile dysfunction. J Sex Marital Ther. 1999;25:145-150.
35. Mintz D. Unusual care, report: nonpharmacological effects of sildenafil. Psychiatric Services. 2000;51:674-675.
36. Mendels J, Cameran A, Sikes C. Sertraline treatment for premature ejaculation. J Clin Psychopharmacol. 1995;15:341-346.
37. Haensel S, Klem T, Hop W, Slo, A. Fluoxetine and premature ejaculation. J Clin Psychophamacol. 1998;18:72-77.
38. Althof A, Levine S, Corry P, Risen C, Stern E, Kurit D. Clomipramine as a treatment for rapid ejaculation: a double-blind crossover study of 15 couples. J Clin Psych. 1995;56:402-407.
39. Waldinger M, Hengeveld M, Zwindman A. Ejaculation retarding properties of paroxetine in patients with primary premature ejaculation: a double blind randomized study. Br J Urol. 1997;156:1631-1632.
40. Waldinger M, Hengeveld M, Zwindman A, Olivier A. Effect of SSRI antidepressant on ejaculation. A randomized placebo controlled study with fluoxetine, fluvoxamine, paroxetine and citalopram. J Clin Psych. 1998;18:274-281.
41. Waldinger M. SSRIs and ejaculation: a double-blind randomized fixed dose study with paroxetine and citalopram. J Clin Psychopharmacol. 2001;21:556-560.
42. Segraves RT, Saran A, Segraves K, Maguire E. Clomipramine versus placebo in the treatment of premature ejaculation: a pilot study. J Sex Marital Ther. 1993;19:198-200.
43. McMahon C, Touma K. Treatment of premature ejaculation with paroxetine hydrochloride. Int J Imp Res. 1999;11:241-245.
44. Morales A. Hormonal erectile dysfunction. Evaluation and management. Urol Clin N America. 2001;28:279-288.
45. Tenover JL. Male hormonal replacement therapy including andropause. Endocrinol Metab Clin North Am. 1998;27:969-987.
46. Wang C. Transdermal testosterone gel improves sexual function, mood, Muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab. 2000;85:2839-2853.
47. Waxenberg SE, Drellich MG, Sutherland AM. Changes in female sexuality after adrenalectomy. J Clin Endocrinol Metab. 1959;19:197-202.
48. Greenblatt RB. Hormone factors in libido. J Clin Endocrinol. 1942;3:305-308.
49. Segraves RT. Female sexual disorders:psychiatric aspects. Canadian J Psychiatry. 2002;47:419-425.
50. Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosomatic Medicine. 1987;49:397-409.
51. Basson R. Androgen replacement for women. Canadian Family Physician. 1999;45:2100-2107.
52. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Eng J Med. 2000;343:682-688.
53. Tuiten A, van Honk J, Koppeschaar H, Bernaards C, Thijssen J, Verbaten R. Time course of effects of testosterone administration on sexual arousal in women. Arch Gen Psychiatry. 2000;57:149-153.
54. Segraves RT, Croft H, Kavoussi R, et al. Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women. J Sex Marital Ther. 2001;27:303-316.
55. Arlt W, Callies F, van Vlijmen J, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Eng J Med. 1999;341:1013-1020.
56. Guay AT, Jacobsen J. decreased free testosterone and dehydroepiandrosterone-sulfate (DHEA-S) levels in women with decreased libido. J Sex Marital Ther. 2002;28(suppl 1):129-142.
57. Munarriz R, Talakoub L, Flaherty E, et al. Androgen replacement therapy with dehydroepiandsrostrerone for androgen insufficiency and female sexual dysfunction: androgen and questionnaire results. J Sex Marital Ther. 2002;28(suppl 1):165-174.
58. Meston CM, Heiman J. Acute dehydroepiandrosterone effects on sexual arousal in pre-menopausal women. J Sex Marital Ther. 2002;28:53-60.
59. Meston CM & Frohlich PF. The neurobiology of sexual function. Arch Gen Psychiatry. 2000;57:1012-1030.
60. Hackbert L, Heiman JR. Acute dehydroepiandrosterone DHEA effects on sexual arousal in postmenopausal women. J Women's Gend Based Med. 2002;11:155-162.
61. Giuliano F, Rampin O, Alard J. Neurophysiology and pharmacology of female genital sexual response. J Sex Marital Ther. 2002;28(suppl 1):101-122.
62. Bartik B, Goldberg J. Female sexual arousal disorder. In: Leiblum SR, Rosen RC, eds. Principles and Practice of Sex Therapy. New York, NY; Guilford Press: 2000:85-117.
63. Meston CM, Heiman JR. Ephedrine-activated physiological sexual arousal in women. Arch Gen Psychiatry. 1998;55:652-658.
64. Islam A, Mitchell J, Rosen R, et al. Topical alprostadil in the treatment of female sexual arousal disorder.a pilot study. J Sex Marital Ther. 2001;27:531-540.
65. Rosen RC, Phillips NA, Gendrano N, Ferguson DM. Oral phentolamine and female sexual arousal disorder: a pilot study. J Sex Marital Ther. 1999;25:137-144.
66. Rubio-Aurioles E, Lopez M, Lipezker M, et al. Phentolamine mesylate in postmenopausal women with female arousal disorder. J Sex Marital Ther. 2002;28(suppl 1):S205-S216.
67. Becher EF, Bechara A, Casabe A. Clitoral hemodynamic changes after a topical application of alprostadil. J Sex Marital Ther. 2001;27:405-410.
68. Basson R, McInnes R, Smith M, Hodgson G, Spain T, Koppiker N. Efficacy and safety of sildenafil in estrogenized women with sexual dysfunction. Obstet Gyn. 2000;96(suppl 1):54.
69. Basson R, McInnes R, Smith M, Hodgson G, Koppiker N. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Women's Health Gender Based Medicine, 2002;11:367-377.
70. Caruso S, Intelisano G, Lupo L, Agnello C. Premenopausal women affected by sexual arousal disorder treated with sildenafil:a double-blind cross-over study. BJOG. 2001;108:623-628.
71. Segraves KB, Segraves RT. Hypoactive sexual desire disorder:prevalence and co-morbidity in 906 patients. Sex Marital Therapy. 1991;17:1-9.
72. Fugl-Meyer, KS. Epidemiology of female sexual function. Paper presented at: Female Sexual Function Forum; Boston, Mass: October, 2001
73. Salerian AJ, Deibler WE, Vittone BJ, et al. Sildenafil for psychotropic-induced sexual dysfunction in 31 women and 61 men. J Sex Marital Ther. 2000;26:133-140.
74. Fava M, Rankin M. Sexual functioning and SSRIs. J Clin Psychiatry. 2002;63(suppl 5):13-16.
75. Michelson D, Bancroft J, Targum S, Kim Y. Trepner R, Female sexual dysfunction associated with antidepressant administration:a randomized, placeho-controlled study of pharmacological intervention. Am J Psychiatry. 2000;157:239-243.
76. Landen M, Eriksson E, Agren H. Fahlen T. Effect of huspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol. 1999;19:268-275.
77. Kennedy SH, McCann SM, Masellis M, et al. Combining bupropion SR with venlafaxine, paroxetine or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry. 2002;63:181-186.
78. Nurnberg HG, Gelenberg AJ, Fava M, et al. Sildenafil for SRI associated sexual dysfunction: a three-center six weeks double blind placebo controlled study in 90 men. Poster presented at: New Clinical Drug Evaluation Unit. Albuquerque, NM; 1999.
79. Nurnberg HG, Gelenberg A, Hargreave TB, Harrison WM, Siegel RL, Smith MD. Efficacy of sildenafil citrate for the treatment of erectile dysfunction in men taking serotonin reuptake inhibitors. Am J Psychiatry. 2001;158:1926-1928.